中国中西医结合皮肤性病学杂志2026，Vol.25Issue(2)：114-119,6.
YKL-40和CLEC4G在特应性皮炎变化及其与临床特征的相关性中的表达
Changes in YKL-40 and CLEC4G Levels in Atopic Dermatitis and Their Correlation with Clinical Features
摘要
Abstract
Objective In order to investigate the expression of chitinase-3-like protein 1(YKL-40)and C-type lectin domain family 4 member G(CLEC4G)in atopic dermatitis(AD),to evaluate their correlations with disease severity and clinical characteristics,and to observe their changes after dupilumab treatment.Methods A total of 115 patients with AD who attended our hospital from September 2022 to December 2024 were enrolled as the observation group and further subdivided into mild(n=35),moderate(n=40)and severe(n=40)groups according to the scoring atopic dermatitis(SCORAD)index.Thirty-five healthy subjects were selected as the control group.Serum levels of YKL-40,CLEC4G,interleukin-4(IL-4)and IL-13 were measured.Moderate-to-severe AD patients received subcutaneous dupilumab treatment,and the above indicators were detected before treatment and after four weeks of treatment.Results Serum YKL-40 level in the observation group was significantly higher than that in the control group,while CLEC4G level was significantly lower,the difference was statistically significant(both P<0.05).Across the three severity subgroups,YKL-40 and CLEC4G levels had significant statistical differences(all P<0.05).There was a positive correlation between YKL-40 level and SCORAD(r=0.743,P<0.001),and a negative correlation between CLEC4G level and SCORAD(r=-0.787,P<0.001).YKL-40 and CLEC4G level had significant statistical differences in patients with different disease severity,family history of AD,and allergy history(all P<0.05),while no significant statistical differences were observed in other clinical characteristics(all P＞0.05).The areas under the receiver operating characteristic(ROC)curve(AUCs)for AD diagnosis were 0.782(95%CI:0.710-0.853)for YKL-40 and 0.809(95%CI:0.748-0.871)for CLEC4G.After four weeks treatment with of dupilumab,moderate-to-severe AD patients showed significant decreasing in serum levels of YKL-40,IL-4 and IL-13,the differences were statistically significant(P<0.05),accompanied by a significant increasing in CLEC4G level,the difference was statistically significant(all P<0.05).Conclusion Serum level of YKL-40 and CLEC4G can serve as potential biomarkers of AD,which are significantly correlated with the severity of AD.Dupilumab treatment can significantly regulate the expression of YKL-40 and CLEC4G,which may be potential targets for the treatment of AD.关键词
特应性皮炎/几丁质酶3样蛋白1/C型凝集素结构域家族4成员G/相关性分析/度普利尤单抗Key words
Atopic dermatitis/Chitinase 3-like protein 1/C-type lectin domain family 4 members G/Correlation analysis/Dupilumab分类
医药卫生引用本文复制引用
赵天,石志娜,张静,耿春杰,袁耀辉..YKL-40和CLEC4G在特应性皮炎变化及其与临床特征的相关性中的表达[J].中国中西医结合皮肤性病学杂志,2026,25(2):114-119,6.基金项目
邢台市重点研发计划自筹项目(编号:2022ZC178). （编号:2022ZC178）
